EDQM Publishes Elemental Impurities Guideline

News
Article

The agency published a guideline for the implementation of ICH Q3D.

On August 4, 2016, the European Directorate for the Quality of Medicines & HealthCare (EDQM) published

Implementation of ICH Q3D in the Certification Procedure

to provide guidance on the implementation of the International Council for Harmonization’s (ICH) Q3D Guideline for Elemental Impurities as it applies to Certificates of Suitability (CEP). The new EDQM guidance applies to both new and existing CEPs.

EDQM’s policy for elemental impurities covered by a CEP to the monographs of the European Pharmacopoeia (Ph.Eur.), in relation to substances within the scope of ICH Q3D, is detailed in the new guidance. The guidance explains the implementation of the policy, which includes providing a risk management summary (RMS) for elemental impurities that may be present in the manufacturing process of the final substance. EDQM provides instructions on how to build an RMS and how to define a control strategy.  The guidance also details what information should be provided on the CEP.

ICH Q3D, which went into effect in the European Union in June 2016 for new marketing authorization applications and applies to authorized medicinal products starting in December 2017, emphasizes a risk-based approach to limiting elemental impurities. It addresses 24 elements and provides permitted daily exposure limits. ICH Q3D considers multiple aspects of manufacturing including equipment, water, and container-closure systems.   

Source: EDQM

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments